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DNA Blood Mini kit (Qiagen, UK). The detection of the R178G
mutation was performed after ampliﬁcation of the exon 6 of
SLC40A1 gene by PCR and subsequent restriction-digestion (RFLP,
Restriction Fragment Length Polymorphism) analysis (Fig. 1). The
protocol was designed based on the fact that the mutation results
in the creation of a DNA sequence that is not recognized by the
restriction enzyme HpyAV (New England Biolabs, UK). All PCR
and digestion procedures were carried out in the PCR-engine
apparatus PTC-200, MJ-Research (Watertown-Massachusetts),
while the PCR and digestion products were analyzed in 2.5%
TBE agarose gels (Fig. 1). For the conﬁrmation of PCR–RFLP
results, randomly chosen PCR products were puriﬁed by Qiagen
PCR Puriﬁcation System (Qiagen, UK) and directed sequenced
using an ABI Prism 310 Genetic Analyzer (Applied Biosystems,
Foster City, CA) and a Big Dye pTerminator DNA sequencing kit
(Applied Biosystems).
No individual carrying the SLC40A1-R178G mutation was
found, supporting, in parallel with the ﬁndings of the above men-
tioned family, its causative relation with ferroportin disease.
Finally, we would like to emphasize that the speciﬁc PCR–
RFLP protocol utilized in this study can also be applied for the
detection of another mutation found in the 178R amino acid, pro-
viding a rapid and reliable approach for the analysis of speciﬁc
alterations of the SLC40A1 gene.
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Fig. 1. SLC40A1-R178G mutation identiﬁed by PCR–RFLP. The forward and
reverse primers used were 50-CTTACCTGCCTCTTTC-30 and 50-CATTGTGTTCAGTT-
TACC-30 , respectively. The PCR conditions were: 2 min at 94 C followed by 33
cycles (94 C for 30 s, 54 C for 30 s, 72 C for 30 s), and 5 min at 72 C after the
last cycle. A 293 bp fragment was ampliﬁed by PCR and subjected to HpyAV
digestion (New England Biolabs, UK) at 37 C for 8 h. The wild-type allele contains
two HpyAV sites resulting in 139, 112, and 42 bp fragments, while the presence of
a 178G allele results in an additional 181 bp fragment, due to the abrogation of a
digestion site. M: 200 bp ladder molecular weight marker (Invitrogen, UK); lane
1: blank, negative PCR control; lane 2: PCR product and lane 3: digestion products
of a sample heterozygous for the SLC40A1-R178G mutation; lane 4: PCR product
and lane 5: digestion products of a wild-type sample. The 42 bp fragments were
not visible on agarose gels.
JOURNAL OF HEPATOLOGYReply to: SLC40A1-R178G mutation and ferroportin diseaseTo the Editor:
Clearly, the observation that R178G was not found in 253
ethnically matched bone marrow donors, supports Dr. Speletas’
and his colleagues’ notion that R178G is a rare sequence variant.
The concept that R178G is a disease causing mutation is chal-Journal of Hepatology 2lenged by the apparently incomplete penetrance of this mutation
in the family reported. Additional clinical information provided in
the letter above further supports the notion that the index case
and her mother are affected by an iron storage disease that can
be regarded as a genuine ferroportin disease. However, absence011 vol. 55 j 729–733 731
Letters to the Editor
of hyperferritinemia in the oldest individual identiﬁed with the
R178G mutation can either be interpreted as incomplete pene-
trance or as evidence against R178G being a disease causing
mutation. This raises an important question: When do we con-
sider a genetic variant disease causing?
In the age of genome wide association studies and whole gen-
ome sequencing, this question becomes increasingly important.
The frequency of a sequence variant does not necessarily reﬂect
the functional importance because even in ferroportin related
iron overload, common polymorphisms in SLC40A1, such as
Q248H, have been reported as a strong risk factor for hyperferr-
itinemia [1]. On the other hand, V72F represents a rare sequence
variant that may still be of little functional consequence [2].
Taken together, a genetic variant is likely to be disease caus-
ing if the mutation segregates with the disease within a family
and is not present in an ethnically matched population. In silico
studies can provide further evidence for the functional conse-
quence of genetic variations, which – for R178G – supports
the notion that this mutation is disease causing [3]. Finally,
functional and structural studies of the mutant protein in cells
or knock-in animals have not been reported for R178G. Hence,
the question remains whether R178G is disease causing or not.
This uncertainty is paradigmatic for ferroportin disease and is
expected to increase, because it remains to be resolved how to
analyze millions of sequence variants detected by next
generation sequencing technology [4] that, at the threshold of
entering clinical practice, can be interpreted and functionally
analyzed.
Distinct, alcohol-modulated
on progression of c
To the Editor:
Recent large-scale genetic studies in patients with chronic
hepatitis C (CHC) provide evidence for a signiﬁcant role of host
genetic factors in its natural course [1], response to therapy [2],
and incidence of therapy-related adverse effects [3]. Recently, a
variant (rs738409 G>C) within the gene coding for patatin like
phospholipase domain containing-3 (PNPLA3) was found associ-
ated with liver fat content and progression of non-alcoholic fatty
liver disease (NAFLD) and alcoholic liver disease (ALD) [4,5].
PNPLA3 modulates storage of triglycerides in hepatocytes by a
yet unknown mechanism possibly related to lipid hydrolysis or
cross-talk with other mechanisms governing lipid storage with
consecutive ‘‘lipid trapping’’ in those patients carrying genotype
PNPLA3 rs738409 GG [6]. Although there is agreement on the
important functional role of viral epitopes in the evolution of ste-
atosis in CHC [7,8], host genetic factors, such as PNPLA3 variation,
could further modulate the accumulation of liver fat. In this issue
of the Journal of Hepatology and elsewhere, two independent
groups of researchers from distinct European regions demon-
strate a signiﬁcant association of PNPLA3 rs738409 G with ﬁbro-
sis, steatosis, and inﬂammation in patients with CHC [9,10]. Cai
et al. included 626 patients from the Swiss Hepatitis C Cohort
Study and found a signiﬁcant association of PNPLA3 rs738409
GG carriage with steatosis of any degree in genotype non-3
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patients, whereas no impact of this variant on the stage of liver
ﬁbrosis was observed [9]. Regarding this lack of association, a
stratiﬁed analysis of rs738409 towards steatosis and ﬁbrosis in
obese and/or alcoholic CHC patients would be interesting,
because BMI and alcohol consumption were independently asso-
ciated with the degree of steatosis in this cohort.
We ourselves tested a possible association of PNPLA3
rs738409 with the severity of steatosis and ﬁbrosis in 605 previ-
ously untreated Caucasian patients with CHC from three German
University centres (Table 1). Assuming a recessive model control-
ling for sex, age, BMI, andviral genotype3, both thepresenceof ste-
atosis (grades 1–3 versus grade 0) and cirrhosis (METAVIR stage 4
versus stage <4) was signiﬁcantly associated with genotype
PNPLA3 rs738409 GG. Upon stratiﬁcation of alcohol intake into
abstainers (<30 g/day) and at-risk drinkers (>30 g/day), a distinct
risk pattern emerged: while genotype rs738409 GGwas primarily
relevant for steatosis in abstainers, its association with pre-treat-
ment ﬁbrosis was restricted to at-risk drinkers. Our data are in line
with the large study from Valenti and coworkers from Italy [10],
who found a signiﬁcant association of genotype PNPLA3
rs738409 GG with steatosis and ﬁbrosis, no-response to antiviral
treatment, and the occurrence of hepatocellular carcinoma.
Together, data from these three independent studies lend
strong support for a signiﬁcant role of PNPLA3 rs738409 not only
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